Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Wegovy (semaglutide), a once-weekly GLP-1 agonist, has already overtaken Novo Nordisk's once-daily obesity therapy Saxenda (liraglutide) in terms of the number of physicians prescribing the two drugs.

Novo Nordisk (NVO) announced that the Food and ... along with its existing indications for adults with type 2 diabetes to improve glycemic control and to reduce the risk of major cardiovascular ...

The EMA's main advisory committee has backed approval of Novo Nordisk's oral GLP-1 agonist Rybelsus, a key pipeline drug in its type 2 diabetes franchise. Rybelsus (semaglutide) is the first GLP-1 ...